Zodon 264mg

Quick links to important sections

Zodon 264mg

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zodon 264mg

What is Zodon 264mg? Defining its Core Identity

Property Description
Active ingredient Clindamycin
Form Oral Solid Preparation (Capsule or Tablet)
Pharmacological class Lincosamide Antibiotic
Common use Anti-infective agent (general purpose)
Origin Semi-synthetic

Zodon 264mg is a systemic, prescription-only medicine that utilizes Clindamycin as its active pharmaceutical ingredient. It is classified as a Lincosamide antibiotic, a class employed to fight susceptible bacterial infections by preventing growth. It is recognized for its role as an anti-infective agent.

This preparation is a single-ingredient product and is a semi-synthetic derivative of the parent Lincosamide, Lincomycin. The specific 264mg strength distinguishes this formulation, providing a measured unit dose suitable for oral administration to manage systemic infection.


Composition and General Purpose

Zodon 264mg is manufactured as an oral solid dosage form, typically a capsule or tablet, designed for systemic administration. The use of this specific strength allows for accurate, consistent delivery of Clindamycin throughout the body. Clindamycin is recognized for its activity against certain pathogenic strains, including Gram-positive aerobes and many anaerobes. This makes its general purpose critical in scenarios where eliminating these specific bacteria is necessary, such as managing a deep-seated soft tissue infection.


How Does Clindamycin Work to Stop Bacteria?

The function of Clindamycin is based on its ability to directly inhibit protein synthesis within susceptible bacteria. This mechanism is achieved by Clindamycin binding reversibly to the 50S ribosomal subunit, which is essential for the bacteria's ability to build proteins for growth and replication.

This molecular action results in a predominantly bacteriostatic effect, meaning the medicine limits the expansion of the infectious population. By blocking this fundamental biological function, Zodon 264mg aids the body's natural immune system in resolving the overall bacterial infection.

Regulatory References

  1. Clindamycin - StatPearls

What side effects are possible with Zodon 264mg?

Official Safety Profile of Zodon 264mg

The possible side effects and safety characteristics of Zodon 264mg (Clindamycin) are officially documented and classified by regulatory authorities based on system-organ classes and frequency of occurrence.

Adverse Reactions Classified by Frequency

Classification Examples of Documented Adverse Reactions
Common ( ge 1/100 to < 1/10) Diarrhea, Abnormal liver function tests
Uncommon ( ge 1/1,000 to < 1/100) Abdominal pain, Nausea, Vomiting, Skin rash, Urticaria
Frequency Not Known Pseudomembranous colitis, Anaphylactic shock, Severe cutaneous reactions (SJS, TEN)

Systemic and Serious Adverse Reactions

Clindamycin has potential effects documented across multiple physiological systems. The most commonly reported system for adverse effects is the Gastrointestinal System, which includes severe adverse reactions such as pseudomembranous colitis, documented as a potentially life-threatening event. Other affected systems include Hepatobiliary Disorders (e.g., jaundice) and Blood and Lymphatic System Disorders (e.g., leukopenia, agranulocytosis).

Serious adverse events officially listed include the severe gastrointestinal colitis and potentially fatal hypersensitivity reactions such as anaphylactic shock, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN).

Safety Considerations and Constraints

Official labeling notes that the onset of severe gastrointestinal issues, including colitis, may occur during therapy or several weeks after treatment has been completed. The medicine is contraindicated in individuals with known hypersensitivity to clindamycin, lincomycin, or any components of the formulation. Regulatory documents also recommend specific monitoring of liver and kidney function for patients with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information mandates that patients seek immediate medical attention or contact a poison control center in cases of known or suspected overdosage with Zodon 264mg (Clindamycin).


Documented Overdose Profile

Feature Regulatory Documentation Status
Documented Manifestations Primarily an exacerbation of common adverse effects, including severe gastrointestinal disturbances (nausea, vomiting, abdominal pain, and diarrhea).
Physiological Systems Affected Gastrointestinal (most common), Hepatic (transient elevations in liver enzymes), and Cardiovascular (potential for hypotension).
Antidote Information No specific antidote is known for Clindamycin overexposure.
Management Procedures Treatment is restricted to symptomatic and supportive treatment. Hemodialysis and peritoneal dialysis are explicitly stated as not effective at removing the drug from the blood.
Population Notes The potential for drug accumulation and heightened toxicity is noted for patients with pre-existing severe hepatic or renal impairment.

The regulatory profile clearly establishes the need for immediate emergency care, as there is no specific antidote, and standard clearance procedures are ineffective. Management relies on hospital monitoring and supportive care to address documented clinical signs and maintain vital functions, especially for high-risk patients with organ impairment. These official statements define the conditions under which urgent medical help is required.

Therapeutic Uses of Zodon 264mg

What Zodon 264mg treats: Main Uses and Benefits

The role of Zodon 264mg (Clindamycin) is to manage and help address certain serious bacterial infections, particularly those caused by susceptible anaerobic organisms and specific Gram-positive bacteria. Its therapeutic use is relevant in managing conditions where symptoms relate to systemic or deep-seated infection, providing supportive relief for distressing symptomatic patterns. Clindamycin is commonly used to help with managing serious infections, including septicemia, intra-abdominal infections, bone and joint infections, and gynecological infections.

The medication is commonly used across contexts where additional symptomatic support is needed, and may assist with maintaining functional stability when symptoms interfere with daily functioning. It helps address symptom clusters like severe localized swelling, redness, and purulent discharge in conditions such as deep skin and soft tissue abscesses. The application of Zodon 264mg is relevant when the infection requires focused support against bacteria that thrive in low-oxygen environments. Furthermore, it acts as a relevant therapeutic alternative for patients with known penicillin hypersensitivity and also plays a role in managing symptoms as an adjunctive therapy in severe situations like Toxic Shock Syndrome.


Quick Fact: Relief for Deep-Seated Infection Symptoms

Zodon 264mg is generally used to help ease the overall symptom burden associated with serious infections, including high fever and significant pain in affected areas.

Eligibility and Restrictions for Use

Zodon 264mg (Clindamycin) is an antibiotic prescribed for the treatment of specific bacterial infections in dogs, including infected wounds, abscesses, dental infections, and bone infections (osteomyelitis) caused by susceptible organisms like Staphylococcus species.

Who Can Use Zodon 264mg?

Patient Population Indication
Dogs For infections where the bacteria have been proven or strongly suspected to be sensitive to the active ingredient, Clindamycin.

Who Cannot Use Zodon 264mg?

Zodon 264mg is contraindicated and should not be used in the following circumstances:

  • Hypersensitivity: Animals with a known allergy or hypersensitivity to Clindamycin, the active ingredient, any of the excipients, or to Lincomycin (a related lincosamide antibiotic).
  • Specific Species: It must not be administered to rabbits, hamsters, guinea pigs, chinchillas, horses, or ruminants, as ingestion by these species can result in severe, potentially life-threatening gastrointestinal disturbance.
  • Neonates: Use is generally not recommended in newborn animals.
  • Systemic Impairment: Caution is advised in patients with severe renal or very severe hepatic disturbances, especially those with metabolic abnormalities. These animals require careful dose adjustment and close clinical and laboratory monitoring.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Zodon (Clindamycin) can interact with several other medicinal products, requiring careful consideration before use. The most significant concern involves other antibiotics, specifically macrolides like Erythromycin. Combining Clindamycin with Erythromycin or other macrolide antibiotics is not recommended due to potential antagonistic effects, where the action of both drugs may be reduced. This is due to both drug classes binding to the same site on the bacterial ribosome, which may also increase the risk of cross-resistance.

Clindamycin has inherent neuromuscular blocking properties. When administered concurrently with other neuromuscular blocking agents (used in anesthesia, such as Atracurium or Vecuronium), Clindamycin may enhance their effects, potentially leading to prolonged muscle weakness or paralysis. Use with this class of medicines requires caution and close monitoring.

Concomitant use with the immunosuppressant Cyclosporin is generally advised against, as Clindamycin may reduce Cyclosporin's plasma levels, potentially leading to a loss of its therapeutic effect. Similarly, the simultaneous use of Clindamycin and Aminoglycoside antibiotics (e.g., Gentamicin) is associated with a risk of adverse effects, including the potential for acute renal failure.

To ensure proper absorption, products containing certain mineral-based gastrointestinal protectants, such as Aluminium salts and hydroxides or kaolin, should be spaced and administered at least two hours before Clindamycin.

Mechanism of Action

How Zodon 264mg Works: Mechanism of Action

Zodon (Clindamycin) exerts its mechanism of action by selectively targeting the 23S ribosomal RNA (rRNA) component of the bacterial 50S ribosomal subunit. This interaction is a specific, reversible binding event that occurs within the pathogen's cellular machinery.

This molecular binding action blocks the elongation phase of the bacterial translation pathway, which is the process of synthesizing proteins. By interrupting the creation of necessary structural and enzymatic proteins, the drug prevents cell growth and division, resulting in bacteriostasis. This physiological limitation on pathogen multiplication lowers the total biological load of susceptible organisms in the body, facilitating the host's inherent immune response.

This mechanism is subject to limitation if the bacterial target site is modified, typically through methylation mediated by the Erm enzyme, which sterically interferes with drug attachment.

Dosage and Administration Information

How to Use Zodon 264mg: Administration Guidelines

Zodon 264mg (Clindamycin) is used as a systemic anti-infective agent. Administration is guided by the prescribed route, dosage, and frequency.


Administration and Dosage

The Zodon 264mg product is an oral solid preparation designated for oral administration. Clindamycin is also available in formulations for intravenous (IV) or intramuscular (IM) injection, which are typically reserved for more serious or hospitalized cases.

Standard Adult Oral Dosing Regimens

Dosing is determined by the severity of the infection. The Zodon 264mg unit dose falls within the common ranges used for both serious and more severe infections.

Infection Severity Typical Dosing Range Frequency
Serious Infections 150 mg to 300 mg Every 6 hours
More Severe Infections 300 mg to 450 mg Every 6 hours

Proper Intake Conditions and Duration

To ensure proper administration and minimize the potential for irritation, specific procedural steps are followed:

  • Swallowing: The capsule is swallowed whole with a full glass of water (e.g., 6-8 ounces).
  • Position: It is advised to not lie down for at least 30 minutes after taking the capsule to prevent irritation of the esophagus.
  • Food: Capsules may be taken with or without food as absorption is not significantly affected.

Duration of Use

The full prescribed course of therapy must be completed. For infections caused by beta-hemolytic streptococci, treatment typically continues for a minimum of 10 days.


Population-Specific Recommendations

Standard clinical practice indicates that dose reduction is not typically considered necessary for patients with mild to severe renal impairment or hepatic impairment if the medicine is administered every 8 hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the key research findings reported in clinical trials and meta-analyses regarding the use of this combination treatment. The studies evaluated the drug’s components in combination in relation to symptoms associated with the common cold.


Primary Efficacy Research

Research has explored whether this combination treatment may influence the duration and severity of the common cold. Studies examined several outcomes, including symptom reduction and the total length of illness.

Symptom Reduction

  • One meta-analysis of five Randomized Controlled Trials (RCTs) reported that researchers observed findings associated with a decrease in nasal congestion symptoms over the study period.
  • Studies examined the outcome when treatment was initiated at the first sign of symptoms.
  • The decongestant component was included in studies examining the timeframe of change and impact on sinus pressure measurements.

Effect on Illness Duration

Studies were conducted to determine if the treatment affected the time to full recovery. Findings were mixed across different trials, and it is not yet clear whether the treatment significantly alters the overall duration of the common cold. Further research is ongoing in this area.


Safety and Specific Populations

Safety research focused on general tolerability and specific risks in defined patient populations.

General Safety Profile

The studies reported that the treatment was generally tolerated, with minor side effects being the most common finding. Research explored the potential association between exceeding the maximum daily dose and findings related to liver function.

Research in High-Risk Groups

Research investigated the measurements of blood pressure and identified a change associated with one component of the treatment.

  • Research reported that individuals with a history of hypertension were monitored to track changes in blood pressure.
  • Studies did not include participants with severe liver or kidney impairment, and evidence remains limited regarding the safety profile in these specific groups.

Pediatric Research

For pediatric use, studies evaluated a weight-based dose for children aged 6 to 12, and findings related to safety and symptomatic change were reported. Use in children under 6 years of age was not evaluated in these primary studies.

Frequently Asked Questions (FAQ)

Common questions about Zodon 264mg (FAQ)


Q: How quickly can someone expect to feel the effects of Zodon 264mg?

Zodon (Clindamycin) is described as a bacteriostatic agent, meaning its primary action is limiting the growth of susceptible bacteria upon administration. However, official regulatory documents do not specify an exact timeframe for when a patient should expect to see the full clinical signs of improvement. Clinical response may vary depending on the specific type and severity of the infection being treated.


Q: How long does Zodon 264mg stay in your system?

The drug's pharmacokinetic profile indicates that, for individuals with typical renal function, the average elimination half-life of the active ingredient is approximately three hours following oral administration. This half-life, the time it takes for half the drug to be eliminated, may be slightly longer in patients with significantly reduced renal or hepatic function.


Q: Is Zodon 264mg a controlled substance?

No, the active ingredient in Zodon, Clindamycin, is classified as a prescription-only antibiotic medicine. Regulatory records indicate that it is not currently listed as a scheduled drug under official drug control laws.


Q: Is Zodon 264mg known to cause skin rashes?

Official safety documentation indicates that a general skin rash is listed as an uncommon side effect of Zodon. Regulatory information also notes that severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been documented, and the frequency of these severe reactions is described as 'not known'.


Q: Are there age restrictions for who can use Zodon 264mg?

Official prescribing information outlines usage considerations for various patient populations, including adults and pediatric patients. Use in children is generally guided by weight, and specific age groups, such as infants, children, and adolescents, are addressed in the regulatory labeling.


Q: What are the long-term effects of taking Zodon 264mg?

Official regulatory warnings highlight that certain severe adverse reactions, specifically Pseudomembranous Colitis, may occur not only during therapy but also up to several weeks after treatment has been completed. Official texts do not detail a comprehensive, definitive list of long-term effects beyond these specific risks.


Q: Is Zodon 264mg available in other strengths besides 264mg?

Yes, the active ingredient in Zodon, Clindamycin, is available in multiple formulations and strengths beyond the 264 mg oral dose. Official sources list oral capsules in strengths such as 75 mg, 150 mg, and 300 mg, as well as injectable and topical forms.


Q: Why do doctors prescribe Zodon 264mg for [less-known but accepted use]?

Zodon (Clindamycin) is officially indicated for the treatment of various serious infections caused by susceptible bacteria. These approved uses may include specific types of respiratory tract, skin and soft tissue, abdominal, or gynecological infections, as detailed in the drug's official regulatory labeling.


Q: What is the typical timeframe for treatment with Zodon 264mg?

The full duration of treatment is guided by the specific infection. Official regulatory guidance mandates a minimum course of 10 days for infections caused by beta-hemolytic streptococci. The total duration for other conditions may vary as determined by a healthcare provider.


Q: Does Zodon 264mg affect the effectiveness of birth control pills?

Regulatory information notes that the use of certain antibiotics, including Clindamycin, may potentially reduce the effectiveness of hormonal contraceptives. This risk is noted in official documentation when using both medicines concurrently.


Q: Why is Zodon 264mg only available by prescription?

Clindamycin is classified as a prescription-only medicine because it is a potent antibiotic. The use of this medicine necessitates professional oversight due to the requirement for specific diagnosis, appropriate dosing, and monitoring for potentially serious adverse effects, such as Clostridium difficile-associated diarrhea.


Q: How is Zodon 264mg generally tolerated by most people?

Official data indicates that the most commonly reported adverse reactions are generally related to the gastrointestinal system, including diarrhea, abdominal pain, nausea, and vomiting. Most reported side effects are classified as common or uncommon. These classifications are used in regulatory documents to describe how often these effects have been observed in studies.


Q: Are generic versions of Zodon 264mg considered equivalent?

In the United States, the Food and Drug Administration (FDA) requires that generic versions of a brand-name drug must demonstrate bioequivalence. This means the generic product is required to contain the same active ingredient, strength, and dosage form, and must be expected to work in the same way as the original.


Q: What should I do if I miss a dose of Zodon 264mg?

Official patient information typically includes guidance that if a dose is missed, it is described as something to be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is usually described as being skipped to avoid taking a double dose.


Q: Can I take Zodon 264mg if I also take a multivitamin?

Regulatory documents advise caution regarding certain mineral-based products, such as those containing aluminum salts or kaolin (often found in antacids or some supplements). These products should be taken at least two hours before Zodon to support proper absorption of the medicine.

How should Zodon 264mg be stored and disposed of?

Storage Requirements

Zodon 264mg chewable tablets must be stored at a temperature not exceeding 30 C, as stated in the official regulatory documentation. To ensure stability, the product must be kept in its original blister pack and outer carton.

Stability and Handling

The overall shelf life of the product, as packaged for sale, is 3 years. For divided tablets, any remaining portion must be stored in the open blister pack and outer carton and must be discarded after 72 hours (3 days).

Safety and Disposal

To prevent accidental access, the medicine must be stored out of the sight and reach of children and the target animals. Disposal of unused or expired Zodon 264mg must be done according to local requirements, and the product must not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zodon 264mg found in:

A-Z Index: